Efficacy and Effectiveness of TMS Part 1:TMS Success Rates Across Conditions

---

---

When people hear about Transcranial Magnetic Stimulation (TMS) for the first time, one of the first questions they ask is: “Does it actually work?” The answer is yes—but results can vary depending on the condition being treated, the patient’s medical history, and how the treatment is delivered.

TMS has shown powerful effects for major depressive disorder (MDD) and is also showing great promise in other areas like OCD, anxiety, PTSD, migraines, chronic pain, and even smoking cessation.

Let’s take a closer look at how successful TMS is across these conditions.

Major Depressive Disorder (MDD)

TMS is best known for treating depression, especially treatment-resistant depression, where traditional medications have failed.

• Large clinical trials and real-world studies report response rates between 50–70% and remission rates between 25–45% (Carpenter et al., 2012).
• Newer, accelerated protocols like Stanford’s SAINT approach have shown remission rates exceeding 75% in highly resistant patients (Cole et al., 2020).

For many, TMS provides significant relief without the side effects of medication.

Obsessive-Compulsive Disorder (OCD)

TMS was FDA-cleared for OCD in 2018 using a specialized deep TMS coil targeting the anterior cingulate cortex and medial prefrontal cortex.

• Controlled trials found that 30–45% of patients with treatment-resistant OCD experienced meaningful improvement (Carmi et al., 2019).
• Patients often report better control over compulsions and fewer intrusive thoughts, even when medications and therapy alone have failed.

Generalized Anxiety Disorder (GAD)

While TMS is not yet FDA-approved for anxiety, off-label use is growing, especially in clinics treating depression and anxiety together.

• Research shows that stimulating the right dorsolateral prefrontal cortex—an area associated with emotional regulation—can significantly reduce symptoms of GAD.
• Clinical studies report response rates of 40–60%, with many patients experiencing improved calmness, sleep, and reduced panic (Dilkov et al., 2017).

TMS may be especially helpful for patients who cannot tolerate anti-anxiety medications or prefer non-drug interventions.

Post-Traumatic Stress Disorder (PTSD)

TMS is also showing promise as a treatment for PTSD, particularly in veterans and trauma survivors who haven’t responded to therapy or medication.

• Stimulation of the right prefrontal cortex has been shown to help reduce hyperarousal, intrusive memories, and emotional reactivity.
• Meta-analyses and clinical trials have reported symptom reduction in 50–70% of patients, depending on protocol and trauma history (Edinoff et al 2022).

Though still considered off-label, more providers are offering TMS for PTSD due to strong emerging data and the need for alternative treatment options.

Chronic Pain (Including Fibromyalgia and Neuropathic Pain)

TMS has been increasingly studied for pain-related conditions, especially those with a neurological component like fibromyalgia, complex regional pain syndrome (CRPS), and neuropathic pain.

• Stimulation of the primary motor cortex can reduce pain perception by modulating brain regions involved in pain processing.
• Clinical studies have shown moderate reductions in pain and improved function and quality of life, especially when combined with physical therapy or mindfulness-based programs (Leung et al., 2009).

Pain reduction is gradual and usually builds over multiple sessions, making consistency key.

Migraines

TMS was FDA-cleared for treating migraines with aura in 2013, using single-pulse stimulation to interrupt migraine activity.

• When used at the start of a migraine, TMS can shorten the duration and reduce the severity of attacks.
• Patients also report fewer migraine days per month after a full course of treatment, and TMS may reduce medication use for those with medication-overuse headaches (Lipton et al., 2010).

TMS is a non-drug option for patients who can’t tolerate migraine medications or need an alternative approach.

Smoking Cessation

In 2020, the FDA cleared deep TMS for smoking cessation. The protocol targets brain areas involved in craving and impulse control.

• Clinical trials showed that 27% of participants quit smoking after six weeks of TMS, compared to 11% in the placebo group—a statistically significant result (Zangen et al., 2021).
• TMS may also help reduce cravings and increase motivation to quit, especially when paired with behavioral support.

Final Thoughts

TMS has become one of the most versatile tools in brain-based medicine. From depression and OCD to anxiety, PTSD, and even migraines, it offers real relief where medications alone have fallen short.

Each condition requires its own protocol, and not everyone responds—but across studies, the combination of safety, tolerability, and effectiveness continues to make TMS an increasingly trusted treatment in modern psychiatry and neurology.

Sources

1. Carpenter, L. L., et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study. Depression and Anxiety, 29(7), 587–596. https://doi.org/10.1002/da.21969
2. Cole, E. J., et al. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. American Journal of Psychiatry, 177(8), 716–726. https://pubmed.ncbi.nlm.nih.gov/32252538/
3. Carmi, L., Tendler, A., Bystritsky, A., Hollander, E., Blumberger, D. M., Daskalakis, J., … Zohar, J. (2019). Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry, 176(11), 931–938. https://doi.org/10.1176/appi.ajp.2019.18101180
4. Edinoff, A. N., Hegefeld, T. L., Petersen, M., Patterson, J. C., 2nd, Yossi, C., Slizewski, J., Osumi, A., Cornett, E. M., Kaye, A., Kaye, J. S., Javalkar, V., Viswanath, O., Urits, I., & Kaye, A. D. (2022). Transcranial Magnetic Stimulation for Post-traumatic Stress Disorder. Frontiers in psychiatry, 13, 701348. https://doi.org/10.3389/fpsyt.2022.701348
5. Dilkov, D., Hawken, E. R., Kaludiev, E., & Milev, R. (2017). Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. Progress in neuro-psychopharmacology & biological psychiatry, 78, 61–65. https://doi.org/10.1016/j.pnpbp.2017.05.018
6. Leung, A., et al. (2009). rTMS for Suppressing Neuropathic Pain: A Meta-Analysis. Brain Stimulation, 2(4), 199–206. https://www.sciencedirect.com/science/article/pii/S1526590009004684
7. Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Pearlman, S. H., Fischell, R. E., Ruppel, P. L., & Goadsby, P. J. (2010). Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. The Lancet. Neurology, 9(4), 373–380. https://doi.org/10.1016/S1474-4422(10)70054-5
8. Zangen, A., Moshe, H., Martinez, D., Barnea-Ygael, N., Vapnik, T., Bystritsky, A., Duffy, W., Toder, D., Casuto, L., Grosz, M. L., Nunes, E. V., Ward, H., Tendler, A., Feifel, D., Morales, O., Roth, Y., Iosifescu, D. V., Winston, J., Wirecki, T., Stein, A., … George, M. S. (2021). Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World psychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 397–404. https://doi.org/10.1002/wps.20905

Locations

Choose the office that’s most convenient for you. Our Chesterfield and Richmond Heights locations are here to provide accessible, patient-focused care in a welcoming and professional environment.

CHESTERFIELD
112 Chesterfield Commons East Rd.
Chesterfield, MO 63005
314-697-4867

RICHMOND HEIGHTS
1505 S Big Bend Blvd,
Richmond Heights, MO 63117
314-384-1006